After a median time of 28.4 months, 40.6% of patients treated with pembrolizumab for high-risk nonmuscle-invasive bladder unresponsive to bacillus Calmette-Guérin (BCG) therapy had a complete response to the drug, and the median duration of response was 16.2 months.
Investigators performed a literature review to better understand how delays in treatment might affect clinical outcomes in urologic cancer patients, including the risk of upstaging, recurrence, and mortality.
A study found no survival differences between high-grade UTUC patients who at the time of radical nephroureterectomy achieved low-grade disease following neoadjuvant chemotherapy and those who had inherently low-stage disease and did not receive chemotherapy.
Previous retrospective studies have suggested that 5-alpha-reductase inhibitors may beneficial effects on bladder cancer development and/or recurrence, but a prospective cohort study found no protective effect.
Patients who received intravesical BCG instillation following surgery for nonmuscle-invasive bladder cancer had a lower risk of recurrence of upper tract urothelial carcinoma and bladder cancer, a study found.
Patients with high-grade upper tract urothelial carcinoma who respond to neoadjuvant chemotherapy have a reduced risk of death following surgery compared with those who receive adjuvant chemotherapy, a study found.
In a small study, single-dose instillation of mitomycin C immediately following therapeutic ureteroscopy for upper tract urothelial carcinoma was associated with an 87% decreased risk of urothelial recurrence.
Patients who receive epidural anesthesia at the time of radical cystectomy, compared with those who do not, are more likely to have a myocardial infarction and to be readmitted to a hospital within 30 days following surgery.
Adjuvant platinum-based chemotherapy for upper tract urothelial carcinoma within 90-days of nephroureterectomy improves disease-free and metastasis-free survival compared with surveillance, a study found.